Studies published in 2015 have continued to unravel the genomic landscape of thyroid cancer, particularly of its less common forms (such as medullary and anaplastic carcinomas) and of familial forms of thyroid cancer. As a result, new diagnostic and therapeutic markers have been identified and validated for clinical use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
07 January 2016
In the figure originally published online, one of the genes was incorrectly listed as HABP3. This has been corrected to HABP2 for the print, HTML and PDF versions of the article.
References
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014).
Ji, J. H. et al. Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genet. 11, e1005467 (2015).
Kelly, L. M. et al. Identification of the transforming STRN−ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc. Natl Acad. Sci. USA 111, 4233–4238 (2014).
Kunstman, J. W. et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet. 24, 2318–2329 (2015).
Gara, S. K. et al. Germline HABP2 mutation causing familial nonmedullary thyroid cancer. N. Engl. J. Med. 373, 448–455 (2015).
Sosa, J. A., Hanna, J. W., Robinson, K. A. & Lanman, R. B. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 154, 1420–1426 (2013).
Nikiforov, Y. E. et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid 25, 1217–1223 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Y.E.N. has served as a consultant for Quest Diagnostics. The employer of Y.E.N., UPMC, has a commercial service agreement with CBLPath to offer molecular testing for thyroid nodules.
Rights and permissions
About this article
Cite this article
Nikiforov, Y. Molecular landscape of thyroid cancer continues to be deciphered. Nat Rev Endocrinol 12, 67–68 (2016). https://doi.org/10.1038/nrendo.2015.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.217
